Clinical Trial: A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis

U.S., Aug. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07754786) titled 'A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis' on Aug. 05.

Brief Summary: This study is expected to include approximately 520 patients with moderate to severe AD, and they will be randomly assigned to the treatment group (IBI3027) and the control group (Dupilumab Injection ) in a 1:1 ratio.

Study period: It includes a screening period (4 weeks), a treatment period (44 weeks), and a follow-up period (8 weeks).

After screening is completed, participants will be randomly grouped in a 1:1 ratio. On Day 1 (D1), they will receive a loading dose of either ...